GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia

Neuropsychiatric symptoms in dementia (NPS) collectively refer to behavioral and psychological symptoms affecting individuals with mild cognitive impairment (MCI) or Alzheimer’s disease or related dementia (ADRD). To investigate genetic variants contributing to NPS, we performed a genome-wide association study (GWAS) for nine NPS domains measured by the Neuropsychiatric Symptom Inventory Questionnaire (NPI-Q) in ~12,800 participants from Alzheimer’s Disease Research Centers across the United States. All participants had MCI or dementia and were of European genetic ancestry.

Acknowledgment statement for any data distributed by NIAGADS:

Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.

For investigators using GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia – Vattathil, et al. 2025 data:

The authors are grateful to the ADRC, ADNI, and BioVU participants who made this research

possible. This work was supported in full or in part by the following grants to the authors: R01

AG075827, R01 AG072120, IK4BX005219, I01BX005686; R01 AG079170; T32 HG008341;

1R01MH118233. The contents do not represent the views of the U.S. Department of Veterans

Affairs or the United States Government. The Alzheimer's Disease Genetics Consortium supported the collection of samples used in this study through National Institute on Aging (NIA) grants U01AG032984 and RC2AG036528. The NACC database is funded by NIA/NIH Grant U24 AG072122. VUMC BioVU is supported by numerous sources including the NIH funded Shared Instrumentation Grant S10RR025141 and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2- 0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia – Vattathil, et al. 2025

Description

PI

Related Datasets

Grants

Acknowledgement

Acknowledgment statement for any data distributed by NIAGADS:

For investigators using GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia – Vattathil, et al. 2025 data:

Related Publications